The Potential Role for PARP Inhibitors in Prostate Cancer
Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for... Read More
Prostate Cancer Brachytherapy Outcomes Linked to PSADT
PSA doubling time (PSADT) can predict oncologic and survival outcomes among men who receive brachytherapy for localized prostate cancer (PCa),... Read More
Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment
Selected patients at elevated risk for biochemical recurrence of prostate cancer (PCa) following radical prostatectomy (RP) may benefit from tailored... Read More
Study Supports Prostate Cancer Active Surveillance for Younger Men
Younger men on prostate cancer (PCa) active surveillance (AS) are at lower risk of Gleason score upgrading and pathologic progression... Read More
Shorter ADT Course May Suffice for High-Risk Prostate Cancer
Reducing the duration of androgen deprivation therapy (ADT) from 36 months to 18 months in men with localized high-risk prostate... Read More
PET/CT May Improve Imaging of Recurrent Prostate Cancer
Positron emission tomography (PET)-based imaging may offer a promising alternative to conventional imaging for characterizing the true extent of disease... Read More
Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Aggressive therapy with curative intent appears to be highly successful in men with Gleason score 10 prostate cancer, according to... Read More
Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
Magnetic resonance imaging (MRI) with targeted prostate biopsy added to systematic biopsy for men on active surveillance for low-risk prostate... Read More
Prostate Cancer ADT Ups Thromboembolic Event Risk
Androgen deprivation therapy (ADT) for prostate cancer can increase the risk of thromboembolic events, according to a recent systematic review and meta-analysis... Read More
Automated Bone Scan Index Prognostic for Prostate Cancer
The automated Bone Scan Index (aBSI) is an independent prognostic imaging biomarker of overall survival (OS) in metastatic castration-resistant prostate... Read More